TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03096379

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Enterography performed via magnetic resonance imaging
Study: NCT04070105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compliant Adaptive Energy Storage and Return Foot
Description: The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
Study: NCT04238286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling
Description: All the participants will be placed in a prone position on the bench. Once the subject is settled, we will localize a nodule within the palpable taut band, confirming its presence after inducing local twitch response by palpation. After placing the MTrPs, the area will be sterilized with an alcohol solution colorless spray \[Skin-des. Agupunt ®\]. The puncture method used in the true dry needling groups will be the Hong's fast in-fast out technique, described as the most aggressive technique in the MTrPs treatment, using a needle of 0.32 x 40 mm. The intervention will be implemented until the subject reports the presence of seven local twitch reactions to the controller.
Study: NCT04070105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AllPro
Description: Participants will be fit with a high activity foot designed to be used for walking and running
Study: NCT03064256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training program
Description: Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training program
Description: All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
Study: NCT05989789

Intervention type: DEVICE
Group type: OTHER
Intervention: Radioactive Seed Implantation
Description: In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
Study: NCT00723515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride
Description: sodium fluoride 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluoride calcium fluoride
Description: sodium fluoride 5% + calcium fluoride
Study: NCT02666118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preemptive Interscalene Block - Single Shot
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Interscalene Block- Single Shot
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preemptive Interscalene Block - Catheter
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Interscalene Block - Catheter
Description: Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
Study: NCT00638898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or subcutaneously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Undergo transplantation
Study: NCT00517634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Fluticasone Propionate 100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFC
Description: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT02438670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PID control algorithm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC control algorithm
Study: NCT04026256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: teriparatide daily subcutaneous injection
Study: NCT00737152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAS 130 with diet and exercise
Description: Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
Study: NCT04102553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18-PSMA-1007
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-PSMA-1007
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18-Fluorocholine
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study: NCT03502044

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Kinetic Oscillation Stimulation (KOS)
Description: 10 minutes inactive KOS treatment in each nasal cavity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Kinetic Oscillation Stimulation (KOS)
Description: 10 minutes active KOS treatment in each nasal cavity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Active Kinetic Oscillation Stimulation (KOS)
Description: 10 minutes active KOS treatment in each nasal cavity.
Study: NCT04102553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18-Fluorocholine
Description: Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
Study: NCT01512680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education to Functional Insulin Therapy
Description: * Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary
Study: NCT03497091

Intervention type: OTHER
Intervention: Enteral Formula
Description: Enteral Feeding with an amino acid-based formula
Study: NCT03705780

Intervention type: OTHER
Group type: OTHER
Intervention: the short OSAS scale
Description: Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fentanyl test
Description: In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
Study: NCT01352624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: $AFE
Description: $teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
Study: NCT02944305

Intervention type: PROCEDURE
Intervention: Endotracheal intubation
Description: Endotracheal intubation under direct laryngoscopy using McIntosh blade
Study: NCT04026256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: teriparatide daily subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: denosumab subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: denosumab subcutaneous injection
Study: NCT04543890

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hyperfractionated radiotherapy
Description: Thoracic radiotherapy (45 Gy/30 fractions) for the Hyperfractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).
Study: NCT00534677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: 2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
Study: NCT01963013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-returning catheter valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional urine bag
Study: NCT03221608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery and HIPEC with Lobaplatin
Description: The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without HIPEC
Description: The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
Study: NCT00266929

Intervention type: PROCEDURE
Intervention: surgical
Description: surgical treatment of odontoid fractures
Study: NCT00534677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
Study: NCT00266929

Intervention type: PROCEDURE
Intervention: conservative treatment
Description: conservative stabilization of fractures
Study: NCT00098722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized background therapy
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc (UK-427,857)
Description: maraviroc (UK-427,857) 150 mg taken twice daily
Study: NCT01051024

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diamel
Description: Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
Study: NCT00812370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
Study: NCT03896776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up! 3.0
Description: KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep It Up! 3.0
Description: KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
Study: NCT01108705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, until disease progression or toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, once daily, until disease progression or toxicity
Study: NCT02862613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT00098722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: optimized background therapy
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized background therapy
Description: \[OBT (3-6 drugs based on treatment history and resistance testing)\]
Study: NCT01981200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training in AECOPD
Description: The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.